Reduced fetal movement intervention Trial-2 (ReMIT-2): protocol for a pilot randomised controlled trial of standard care informed by the result of a placental growth factor (PlGF) blood test versus standard care alone in women presenting with reduced feta
Armstrong-Buisseret, Lindsay; Mitchell, Eleanor; Hepburn, Trish; Duley, Lelia; Thornton, Jim G.; Roberts, Tracy E.; Storey, Claire; Smyth, Rebecca; Heazell, Alexander E. P.
ELEANOR MITCHELL ELEANOR.MITCHELL@NOTTINGHAM.AC.UK
TRISH HEPBURN Trish.Hepburn@nottingham.ac.uk
Senior Medical Statistician
Jim G. Thornton
Tracy E. Roberts
Alexander E. P. Heazell
Forty percent of babies who are stillborn born die after 36 weeks gestation and have no lethal structural abnormality. Maternal perception of reduced fetal movement (RFM) is associated with stillbirth and is related to abnormal placental structure and function. The ultimate objective of this trial is to assess whether for women with RFM, intervention directed by measurement of placental biochemical factors in addition to standard care improves pregnancy outcome compared with standard care alone. This is the protocol for a pilot trial to determine the feasibility of a definitive trial and also provide proof of concept that informing care by measurement of placental factors improves neonatal outcomes.
ReMIT-2 is a multicentre, pilot randomised controlled trial of care informed by results of an additional placental factor blood test versus standard care alone for women presenting with RFM at or after 36+ 0 weeks gestation. Participants will be randomised 1:1 to the intervention arm where the blood test result is revealed and acted on, or to the control arm where the blood sample is not tested immediately and therefore the result cannot be acted on. All participants will be followed up six weeks after delivery to assess their health status and views of the trial, along with healthcare costs. A sub-group will be interviewed within 16 weeks after delivery to further explore their views of the trial. Outcomes to determine feasibility of a definitive trial include number of potentially eligible women, proportion lost to follow-up, clinical characteristics at randomisation, reasons for non-recruitment, compliance with the trial intervention and views of participants and clinicians about the trial. Proof of concept outcomes include: rates of induction of labour; Caesarean birth; and a composite neonatal outcome of stillbirths and deaths before discharge, 5-min Apgar score less than 7, umbilical artery pH les than 7.05 and admission to neonatal unit for more than 48h.
Discussion: Results from this pilot trial will help determine whether a large definitive trial is feasible. Such a study would provide evidence to guide management of women with RFM and reduce stillbirths.
Trial registration: ISRCTN Registry, ISRCTN12067514. Registered on 8 September 2017.
Armstrong-Buisseret, L., Mitchell, E., Hepburn, T., Duley, L., Thornton, J. G., Roberts, T. E., …Heazell, A. E. P. (2018). Reduced fetal movement intervention Trial-2 (ReMIT-2): protocol for a pilot randomised controlled trial of standard care informed by the result of a placental growth factor (PlGF) blood test versus standard care alone in women presenting with reduced fetal movement at or after 36+ 0 weeks gestation. Trials, 19, 1-13. https://doi.org/10.1186/s13063-018-2859-1
|Journal Article Type||Article|
|Acceptance Date||Aug 13, 2018|
|Online Publication Date||Oct 1, 2018|
|Publication Date||Oct 1, 2018|
|Deposit Date||Oct 9, 2018|
|Publicly Available Date||Oct 10, 2018|
|Peer Reviewed||Peer Reviewed|
|Keywords||Reduced fetal movement; Placental biomarker; sFlt-1/PlGF ratio; Placenta; Maternal serum; Stillbirth; Perinatal mortality; Feasibility|
Reduced fetal movement intervention Trial2 (ReMIT-2): protocol for a pilot randomised controlled trial of standard care informed by the result of a placental growth factor (PlGF) blood test versus standard care alone in women presenting with reduced fetal
Publisher Licence URL
You might also like
Temporarily quadrupling the dose of inhaled steroid to prevent asthma exacerbations: FAST
Use of biochemical tests of placental function for improving pregnancy outcome